CLT-002

CLT-002 is a peptide that has strong anti-angiogenic activity.

 

---

CLT-002 inhibits endothelial cell proliferation, without advers affects on pericytes or neuronal retinal cells.

Primary retinal capillary endothelial cells (RCEC), pericytes and the Müller cell lines were treated with recombinant CLT-002 at concentrations as indicated for 72 h. The viable cells were quantified using the MTT assay. Values represent absorbance as percentages of respective controls (means ± SD, n=3), and * indicates the values statistically different from the control (p<0.05). These results indicate that CLT-002 selectively kills endothelial cells without destroying other retinal cells important for physiological function.

 

---

Inhibition of ischaemia-induced retinal neovascularization by intravitreal injection of CLT-002.

Retinal neovascularization was induced in newborn Brown Norway rats. Retinal vasculature was examined by angiography at 5 days after the injection of CLT-002 or PBS (control). (A) retina from OIR rat after PBS injection; (B) retina from OIR rats after CLT-002 injection; (C) retina from age-matched normal rats after PBS injection and (D) retina from normal rats after CLT-002 injection. Each image is a representative from four animals of each group. (E) Pre-retinal vascular cells were counted on saggital sections from eight animals. Bars represent cell average numbers per section (means ± SD, n=8). The number in each CLT-002-treated group was compared with the control by Student's t test and * indicates the group with statistical difference from the control (p<0.05)